Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00481676
Other study ID # CIGE025ADE05
Secondary ID
Status Completed
Phase Phase 2
First received June 1, 2007
Last updated September 14, 2011
Start date May 2007
Est. completion date April 2009

Study information

Verified date September 2011
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date April 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion criteria:

- Males or females from 18-70 years of age

- Body weight = 20 kg and = 150 kg and with a total serum IgE level = 30 IU/mL and = 700 IU/mL

- Specific serum IgE anti-TPO level = 8.0 IU/mL, documented within 3 months prior to randomization or time of pre-screening

- Diagnosis of moderate to severe chronic urticaria

- Subject's current episode of chronic urticaria according to the European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum (EAACI/GA2LEN/EDF) guideline at the time of screening

- Current episode of chronic urticaria has not responded to the approved marketed dose of antihistamine for 2 weeks or longer

- Urticaria activity score (UAS) = 0 at any of the 7 days of the first section of the screening period

- UAS7 = 10 at the time of randomization

Exclusion criteria:

- Females of child-bearing potential or breast feeding

- Present or past medical conditions that could have interfered with the study results

- Randomized into any other omalizumab study or who had received omalizumab

- Received investigational drugs within 30 days of enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Omalizumab 75-375 mg
Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
Placebo to omalizumab
Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
Loratadine
All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
Clemastine
All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.

Locations

Country Name City State
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Giessen
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Luebeck
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Munich

Sponsors (1)

Lead Sponsor Collaborator
Novartis

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Weekly Urticaria Activity Score (UAS7) From Baseline to the End of the Study (Week 24) The UAS is a composite diary-recorded score with numeric severity ratings (0=none to 3=intense) for the number of wheals per 24 hours and the intensity of the pruritus. The total daily score (sum of the wheal and pruritus scores) ranges from 0 to 6. Because of variations in chronic urticaria disease intensity, assessment of disease activity was based on a weekly (7 days) UAS score called UAS7, that is, the sum of the daily UASs, ranging from 0 to 42 per week. A higher score indicates worse disease. A negative change score (Week 24 score minus Baseline score) indicates improvement. Baseline to end of the study (Week 24) No
Secondary Number of Patients With Wheals, Erythemas, Pruritus, and Angioedemas at the End of the Study Patients kept a daily diary of the number of wheals and erythema and the severity of pruritus and angioedemas during the study. At the end of the study (Week 24) No
Secondary Standardized (With Respect to Length of Time) Area Under the Curve (AUC) for the Urticaria Activity Score (UAS) From Baseline to the End of the Study (Week 24) The UAS is a composite diary-recorded score with numeric severity ratings (0=none to 3=intense) for the number of wheals per 24 hours and the intensity of the pruritus. The total daily score (sum of the wheal and pruritus scores) ranges from 0 to 6. A higher score indicates worse disease. AUC was calculated from daily UASs where no urticaria medication was taken using the trapezoidal rule. The standardized AUC UAS was calculated as the sum of trapezoids divided by the length of time. Baseline to the end of the study (Week 24) No
Secondary Use of Concomitant and Rescue Medications Data was collected from the patients' diaries about the number of clemastine and loratadine pills taken during the last 7 days of each month of the study. At Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Change in the Dermatology Life Quality Index (DLQI) Score From Baseline to the End of the Study (Week 24) The DLQI is a dermatology-specific quality of life (QoL) questionnaire designed for use in patients over 16 years of age. Patients are asked to respond to each of 10 questions on a 4-point Likert scale in regard to how much their skin problem has affected their life over the last week (0=not at all, 1=a little, 2=a lot, 3=very much). The overall (total) DLQI score (range=0 to 30) is calculated by summing the scores of all 10 questions. The higher the score, the more QoL is impaired. A negative change score (Week 24 score minus Baseline score) indicates improvement. Baseline to the end of the study (Week 24) No
Secondary Change in the Skindex Score From Baseline to the End of the Study (Week 24) Skindex is a 30-item questionnaire with 3 scores (functioning, emotions,symptoms) and a composite score (average scale score) that assesses the effects of skin disease on patients' quality of life (QoL). Item responses are standardized on a scale from 0 to 100. The mean of all 61 items was calculated. A higher score indicates a lower QoL. A negative change score (Week 24 score minus Baseline score) indicates improvement. Baseline to the end of the study (Week 24) No
Secondary Change in Chronic Urticaria Quality of Life (CU-Q2oL) Scores From Baseline to the End of the Study (Week 24) The CU-Q2oL (German version) is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being. It has 23 questions in 3 domains (symptoms, general impairment, difficulties and problems due to urticaria). Patients are asked to respond how much they are troubled by each problem on a 5-point Likert scale (1=not at all to 5=very much). Each domain and the overall (total) scores are normalized to a scale of 1 to 100. A higher score indicates lower QoL. A negative change score (Week 24 score minus Baseline score) indicates improvement. Baseline to the end of the study (Week 24) No
Secondary Patient's Global Assessment of Their Chronic Urticaria Symptoms Patients made a global assessment of their chronic urticaria symptoms on a 4-point Likert scale (none, mild moderate, severe) at Baseline and again at the end of the study. The number of patients in each category is reported. At Baseline and at the end of the study (Week 24) No
Secondary Investigator's Global Assessment of the Patient's Chronic Urticaria Symptoms The investigator made a global assessment of the patient's chronic urticaria symptoms on a 4-point Likert scale (none, mild, moderate, severe) at Baseline and again at the end of the study. The number of patients in each category is reported. At Baseline and at the end of the study (Week 24) No
See also
  Status Clinical Trial Phase
Completed NCT02435238 - AWARE - Chronic Urticaria N/A
Not yet recruiting NCT05513079 - Positive Psychotherapy-Based Counseling (PPT) N/A
Terminated NCT02047136 - Dietary Treatment for Chronic Urticaria N/A
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Terminated NCT01170949 - Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria Phase 2
Completed NCT00598611 - Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Phase 3
Completed NCT01610128 - Development of an Urticaria Control Test N/A
Completed NCT02285023 - The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Completed NCT02285049 - Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test N/A
Completed NCT01715740 - Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Phase 3
Completed NCT01960283 - Methotrexate in the Treatment of Chronic Idiopathic Urticaria Phase 3
Completed NCT01713725 - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria Phase 2
Completed NCT01250652 - Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Phase 4
Completed NCT01111136 - Stress Intervention for Chronic Urticaria N/A
Recruiting NCT01425593 - T Cell Function in Chronic Idiopathic Urticaria N/A
Completed NCT00737451 - Association of Thyroid Autoimmunity and Chronic Urticaria N/A
Completed NCT00619801 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Phase 3
Completed NCT00628108 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months Phase 3
Completed NCT01284426 - Natural History of Chronic Urticaria N/A
Withdrawn NCT01073852 - Hydroxychloroquine Efficacy in Chronic Urticaria N/A